Onconetix Inc
ONCO1.190USD
+0.020+1.71%
收盤 02/09, 16:00（美東）報價延遲15分鐘
328.70K總市值
0.00本益比TTM
關於 Onconetix Inc 公司
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Onconetix Inc簡介
公司代碼ONCO
公司名稱Onconetix Inc
上市日期Feb 18, 2022
CEOFedasz (Karina M)
員工數量5
證券類型Ordinary Share
年結日Feb 18
公司地址201 E. Fifth Street
城市CINCINNATI
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編45202
電話15136204101
網址https://www.onconetix.com/
公司代碼ONCO
上市日期Feb 18, 2022
CEOFedasz (Karina M)
Onconetix Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
658.00
-39.00%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
658.00
-39.00%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q1
FY2024
FY2023
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Switzerland
94.38K
92.87%
United Kingdom
7.25K
7.13%
United States
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 2月3日 週二
更新時間: 2月3日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Altos Venture AG
17.57%
DRW Securities, LLC
3.97%
Citadel Advisors LLC
1.01%
UBS Financial Services, Inc.
0.59%
Schiess (Ralph)
0.51%
其他
76.35%
持股股東
持股股東
佔比
Altos Venture AG
17.57%
DRW Securities, LLC
3.97%
Citadel Advisors LLC
1.01%
UBS Financial Services, Inc.
0.59%
Schiess (Ralph)
0.51%
其他
76.35%
股東類型
持股股東
佔比
Corporation
18.44%
Investment Advisor
4.57%
Individual Investor
1.14%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.21%
Research Firm
0.01%
其他
74.52%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
31
91.66K
5.89%
+62.90K
2025Q3
31
22.38K
5.65%
+17.05K
2025Q2
47
63.91K
38.67%
+44.58K
2025Q1
54
64.94K
25.23%
+43.00K
2024Q4
54
5.57M
44.93%
+3.81M
2024Q3
55
5.45M
45.59%
+5.19M
2024Q2
54
145.05K
20.85%
-52.13K
2024Q1
56
197.34K
30.36%
-46.00
2023Q4
55
198.08K
30.63%
+320.00
2023Q3
52
191.81K
46.53%
-6.38K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Altos Venture AG
273.23K
17.57%
+241.51K
+761.46%
Jul 14, 2025
DRW Securities, LLC
61.78K
3.97%
+61.78K
--
Sep 30, 2025
Citadel Advisors LLC
15.63K
1.01%
+15.63K
--
Sep 30, 2025
UBS Financial Services, Inc.
5.51K
0.35%
+2.71K
+97.28%
Sep 30, 2025
Schiess (Ralph)
7.92K
0.51%
--
--
Dec 12, 2025
Bruhlmann (Christian)
7.19K
0.46%
--
--
Dec 12, 2025
Scablis AG
6.85K
0.44%
+6.85K
--
Sep 24, 2024
New Horizon Health Ltd
6.74K
0.43%
+6.74K
--
Sep 24, 2024
Tower Research Capital LLC
1.57K
0.1%
+1.24K
+375.15%
Sep 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
公告日期
除權除息日
類型
比率
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
